ATOXIGEN is your partner in early R&D. We offer a variety of standardized or customized assays based on the latest innovations in the fields of cellular biology, molecular biology and genomics. Innovative predictive efficacy assays on reconstructed epidermis or primary cell lines from human explants (proteasome, autophagy, detoxification, anti-ageing...); in vitro genotoxicity testing (micronucleus and chromosome aberration tests); endocrine disruptor screening; customized services. Biotechnologies, Testing & Research, Evaluation toxicologique, and Assurance qualité

88 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Scientist-to-Scientist Fluofarma, a Porsolt company, joins drug discovery projects to bring tailored solutions in cell biology and high-content analysis. Specialized in assay design, the French preclinical CRO develops and performs cell-based assays and quantifies biomarkers in blood and tissues using different high-content imaging and flow cytometry technologies. Fluofarma's contract research services are based on the following capacities: CUSTOM BIOLOGICAL MODELS > Generation of primary cell cultures, cell lines, 3D spheroids > Development of multi-cell type culture systems in 2D & 3D > Preclinical and clinical samples : whole blood, solid tissues and tissue microarrays (TMAs) ADAPTATION & DEVELOPMENT OF CELL-BASED …

10 similar entities Type: SMB Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

Our expertise, Your discovery Cellomatics Biosciences Ltd. (www.cellomaticsbio.com) is a laboratory-based Contract Research Organisation (CRO) specialised in Oncology/Immuno-Oncology, Immunology/Inflammation and Respiratory therapeutic areas. Based at Colwick Quays Business Park, Nottingham UK, our experienced scientific team offers bespoke and innovative preclinical in vitro bioassay services to support our client’s drug development programmes. We work with diverse group of global clients including early start-ups, virtual/small to medium sized Biotechnology and Pharmaceutical companies. Multiplex Immunoassay, Target and biomarker validation, In vitro functional assays, Molecular Biology, Receptor binding, Toxicity testing, Immuno-Oncology, Oncology, Immunology, Inflammation, and Respiratory

376 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Exploring together! We support biopharmaceutical research with translational preclinical models. CYNBIOSE is France-based non-clinical research organization. Preclinical CRO, Pharmacokinetics, POC, Efficacy, Immunotherapies, Drug, Early tox, CNS, Infectious diseases, Respiratory diseases, Non clinical, CRO, PK, PD, and TK

69 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Discovery Fueled by Ultra-Sensitivity Quanterix is a company that is digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s ultra-sensitive detection solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the role of biomarkers in the continuum of health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognosis and precise treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research …

92 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Created in 2017, Cyprio is founded on ten years of research at the prestigious French institute for higher education in science and engineering, Ecole Supérieure de Physique et Chimie Industrielles de la ville de Paris (ESPCI Paris), with a strong expertise in the field of 3D cell culture, liver biology and drug development. This makes Cyprio the holder of a unique technology for fabrication of alginate liquid-core capsules containing 3D cellular models physiologically more relevant than traditional monolayer cell culture and compatible with high throughput screening applications. Our first product "HepatoPearl" has been validated as a beneficial in vitro liver …

11 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

AI-Powered Cytometry & Cell Metabolism Profiling At Metafora, we develop innovative and impactful AI-powered cytometry & cell metabolism profiling solutions. We are passionate about cell biology. We leverage our unique cell metabolism and AI-powered data analysis platforms to turn disruptive single-cell technologies into impactful solutions that improve human health. biomarkeurs, cell metabolism, flow cytometry, data analysis, biotechnology, IVD tests, diagnostics, diagnostic tests, cell biology, neurometabolic diseases, metabolic diseases, oncology, multiple myeloma, and research

82 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

A cell-therapy technology company developing artificial membrane-binding proteins for oncology and regenerative medicine CytoSeek's mission is to use cell membrane augmentation technology to unlock the potential of next generation advanced therapies. Our novel cell membrane augmentation technology enables us to add new functionalities to various therapeutic cells. CytoSeek is engaged in proof of principle studies to demonstrate enhancement of cell therapies for cancer. We are looking to partner with cell therapy companies to bring these products to the clinic and ultimately enhance human health. Biochemistry, Immunology, Oncology, Regenerative Medicine, Cell therapies, and Proteins

81 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Discover your favorite frequencies to boost your drug discovery business CellSine provides devices and software that make advanced electrochemical impedance spectroscopy easily accessible to any microbiological researcher. It delivers a platform tool for a that enables a wide variety of biochemical studies. Biotechnology, Cell culture monitoring, Proteïn - Proteïn interactions, Suspension cultures, Receptor signaling, Biofilm maturation, and T lymphocyte activation

206 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Cancer profiling for precision oncology and early cancer detection iCellate develops and provides cancer profiling services for precision oncology. iCellate’s CellMate® is a next generation circulating tumor cell (CTC)-based platform for cancer cell detection and comprehensive biomarker analysis. GeneMate® is an analysis for hereditary cancer and gBRCA testing. Cancer Diagnostics, Circulating Tumor Cells (CTC), Liquid Biopsy, Next Generation Sequencing, CDx, Hereditary Cancer, Early Detection, Cancer, and Solid Tumors

54 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Cellsway is a fresh deep-tech start-up founded in March 2020 in UK to convert the know-how and cutting-edge core technology that have been developed and cultivated at Mikro Biyosistemler Inc. into commercial products to set the gold standard for diagnosis and management of cancer. The flagship product of the company is a liquid biopsy platform which uses a simple blood sample for cancer diagnostics and cancer research. The patent-pending microfluidic technology enables isolation and enumeration of Circulating Tumor Cells (CTCs) from the blood samples of cancer patients.

68 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Providing essential, standardized tools to accelerate breakthroughs in human health Microfluidics | Cytometry | Imaging Standard BioTools delivers the leading proteomic and multi-omic solutions that enable researchers to discover unique biological insights not accessible by other technologies. Mass Cytometry, Tissue Imaging, NGS Library Prep, Genotyping, Gene Expression, Copy Number Variation, Real-Time PCR, and Single-Cell Genomics

184 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Unravelling immune system function, one cell at a time Cellply is a life-science company focused on developing next-generation analytical tools enabling a deep characterization cancer immunotherapies, cell therapies and cell-based biotherapeutics. Our goal is to support the development of novel cancer immunotherapies by accelerating the R&D, advancing the quality control and monitoring the clinical response to these treatments. Through the use of proprietary microfluidic technologies, highly-automated analytical instruments and AI-powered image and data analytics, the Cellply platform defines the function of the immune system one cell at a time, combining functional data with other multiplex data and providing an unprecedented …

92 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. Synthetic Biology

Cellestia Biotech is pioneering innovative therapeutics based on novel modes of action to treat autoimmune diseases and multi-drug resistant cancers. Our clinical stage drug candidate, CB-103, has demonstrated both safety and biological activity in humans. Along with ongoing Phase 2 IITs for multi-drug resistant cancers, CB-103 is also poised to enter a Proof-of-Concept clinical study for graft-versus-host disease (GvHD) Biopharma, Oncology, Precision Medicine, Small Molecules, Targeted Therapy, Biotech, Cancer Therapy, Transcription Factors, Autoimmune Disorders, and Inflammatory Disorders

151 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology